Çukurova Pharmaceutical

Oral Solution

Veterinary Systemic Antibacterial

The Composition

Neo-Lincova Oral Solution contains 250 mg Lincomycin (as Lincomycin hydrochloride) and 140 mg Neomycin (as Neomycin sulphate) in light yellow, clear solution.

Pharmacological Properties

Neo-Lincova contains the active ingredients lincomycin hydrochloride and neomycin sulphate. Lincomycin is a lincosaminide antibiotic derived from Streptomyces lincolnensis. It possesses specific activity against Gram-positive bacteria (B.hemolitik streptococcus, Clostridium perfringens, Mycoplasma sp., Neisseria sp., Acttinomyces sp., Corynebacterium sp., Bacterioides sp ve Camphylobacter sp.), particularly Staphylococcus species and Streptococcus species and has little or no activity against Gram-negative bacteria such as E.coli (except anaerobes). Lincomycin has good activity against mycoplasma. Neomycin is an aminoglycoside antibiotic derived from Streptomyces fradiae. It has a broad spectrum of activity against both Gram-positive bacteria (B.Anthracis, Borrelia sp, L. Monocytogenes), including Staphylococcus species and Streptococcus species, and Gram-negative bacteria (Enterobacter aerogenes, Pasteurella sp, Pr. vulgaris, Salmonella Sp, Shigella sp, H.İnfluenza.), including Escherichia coli. It is more active against Staphylococcus species than against Streptococcus species.

Lincomycin binds to the 50S sub-unit of the bacterial ribosome, thereby inhibiting protein synthesis of the cell. It is generally regarded as a bacteriostatic compound. Neomycin binds to the 30S sub-unit of the bacterial ribosome resulting in a malconformation of binding ribosomal protein due to errors in reading the amino acid coding of the mRNA. Neomycin thus compromises translation and hence bacterial protein synthesis. At high concentrations, the aminoglycosides have also been shown to damage the cellular membrane of bacteria and hence are generally regarded as possessing both bacteriostatic and bactericidal properties.

Neo-Lincova is effective treatment of respiratory tract infections and against Staphylococcus species (both penicillinase and non-penicillinase producers) including Staphylococcus aureus, Streptococcus species including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis, Salmonella, Haemophilus, Pseudomonas, Proteus and coliform bacteria including Escherichia coli in chichens and turkeys.

Administration and Dosage

Neo-Lincova is used orally participating in the drinking water of chicken and turkey. If not otherwise recommended by veterinarians; daily dose is 20-25 mg/kg b.w. for Lincomycin and 10 mg/kg b.w. for Neomycin. Pratically, Neo-Lincova Oral Solution is attended 1000 ml of 1000-1400 liter of drinking water for every 10-14 tonne of body weight.

Drug Withdrawal Period Of Residual

During treatment and after the last treatment, chickens raised for meat should not send for slaughtering 2 days, turkeys 8 days. Not permitted for use in laying birds producing eggs for human consumption.

Type of Packaging
100 - 500 – 1000 - 2500 and 5000 ml white plastic bottles are presented for sale as unboxed.

This part of website targets just for veterinarians. Please confirm your profession as a veterinarian by clicking "Yes" button.
Other wise please select "No" button and continue navigation other parts of website.